Arcutis Biotherapeutics, Inc. (ARQT) - Stock Analysis
Last updated: Jun 13, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Catalyst-rich dermatology name: strong recent ZORYVE revenue, raised 2026 sales guidance, and guidance for continued positive operating cash flow are coupled with a pediatric sNDA filing expected in Q2 2026 and early ARQ-234 Phase 1 progress; despite current technical weakness, any sNDA/regulatory or cash-flow update in the next few days could trigger a sharp rebound from oversold levels.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Gross Margin ⢠Operating Losses ⢠Working Capital ARQT has strong gross margins and adequate liquidity, but persistent operating losses, rising leverage, and heavy working-capital use continue to pressure profitability and capital efficiency.
Price Behavior
Key Price Behavior Insights: ⢠Higher lows ⢠Key support reclaim ⢠Near resistance Support Level: $23.20-$23.40 Resistance Level: $24.60-$25.10 ARQT has shifted into a constructive short-term uptrend over the last month, but it is now nearing $24.60-$25.10 resistance after a sharp ~13% rebound from a $19.50 low.
Sentiment & News
Key News Insights: ⢠Revenue acceleration ⢠Pipeline catalysts ⢠Franchise expansion Arcutis is gaining momentum as ZORYVE drives 65% YoY Q1 revenue growth, with management reaffirming full-year guidance, highlighting upcoming FDA/clinical catalysts, and saying the company is now self-sustaining.
AI Summary
ARQT's investment case has shifted from a cash-burning launch biotech to a scaling dermatology franchise with 65% revenue growth, positive operating cash flow, and improving self-sustainability, but the stock still hinges on ZORYVE execution and successful label expansion before diversification arrives.
Description
Arcutis Biotherapeutics is a clinical-stage biopharmaceutical company developing topical treatments for dermatological conditions. Its lead asset is a roflumilast cream that has completed Phase III trials for plaque psoriasis and atopic dermatitis, and its pipeline includes additional roflumilast and topical JAK1 inhibitor formulations targeting scalp and skin disorders such as seborrheic dermatitis, hand eczema, vitiligo and alopecia areata. The company was incorporated in 2016, changed its name in October 2019, and is headquartered in Westlake Village, California.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Mar 4 | Mar 11 | ARQT | Arcutis Biotherapeutics, Inc. | Catalyst-rich dermatology name: strong recent ZORYVE revenue, raised 2026 sales guidance, and guidance for continued positive operating cash flow are coupled with a pediatric sNDA filing expected in Q2 2026 and early ARQ-234 Phase 1 progress; despite current technical weakness, any sNDA/regulatory or cash-flow update in the next few days could trigger a sharp rebound from oversold levels. | Closed | -0.7% |
| Dec 2 | Dec 9 | ARQT | Arcutis Biotherapeutics, Inc. | Compelling short-term growth supported by strong Q3 revenue growth (+122% YoY), recent FDA pediatric approvals, upcoming Phase 2 topline data in Q1 2026, solid profitability trends, strong liquidity with $191M cash, and a 20% price surge with bullish technical momentum. | Closed | +1.1% |